Chronic heart failure: drug provision, follow-up and application potential of digital technologies
Authors:   Acad. E.I. Chazov National Medical Research Center of Cardiology, Moscow, Russian Federation, Dolgusheva Yu.A. ,   Plekhanov Russian University of Economics, Moscow, Russian Federation, Efremova Yu.E. ,   Acad. E.I. Chazov National Medical Research Center of Cardiology, Moscow, Russian Federation, Gornyakova N.B. ,   Acad. E.I. Chazov National Medical Research Center of Cardiology, Moscow, Russian Federation, Kudrina V.G. ,   Plekhanov Russian University of Economics, Moscow, Russian Federation,   Russian Medical Academy of Continuous Professional Education, Moscow, Russian Federation, Ayrapetyan A.A. ,   Acad. E.I. Chazov National Medical Research Center of Cardiology, Moscow, Russian Federation, Mironov N.Yu. ,   Acad. E.I. Chazov National Medical Research Center of Cardiology, Moscow, Russian Federation,   Plekhanov Russian University of Economics, Moscow, Russian Federation, Bogdanova V.O. ,   Plekhanov Russian University of Economics, Moscow, Russian Federation,   National Medical Research Center for Endocrinology, Moscow, Russian Federation, Sorokin E.V. ,   Acad. E.I. Chazov National Medical Research Center of Cardiology, Moscow, Russian Federation
Published: October 2024

This article is aimed at analyzing and discussing the quality of drug provision for patients with chronic heart failure (CHF), the organization of follow-up and the application potential of digital technologies in the treatment of patients with CHF, the prevalence of which continues to grow in the modern population. Optimal and timely adjusted drug therapy is the basis for effective treatment of patients with CHF. The lack of unified medical information systems and registers of such patients with the possibility of analytical work in most regions of the Russian Federation does not allow to fully assess the drug therapy quality in CHF. Evaluation of drug therapy in patients with CHF on an outpatient basis shows incomplete compliance of CHF treatment with current clinical recommendations. Follow-up conducted within the framework of current regulatory legal acts requires regular monitoring concerning not only the visit frequency, but also of the compliance of laboratory and instrumental study extent with current clinical recommendations. The inclusion of patients with CHF in the intensive outpatient follow-up program will improve the life prognosis of this patient cohort. The development and implementation in practical healthcare of methods for analyzing the digital data arrays, machine learning based on AI will contribute to improving the medical care quality. To improve the quality of medical care in CHF, it is necessary to provide patients with optimal drug therapy (including within the preferential drug provision) in order to conduct high-quality follow-up using modern digital technologies. All this will help to significantly reduce the risk of adverse outcome and hospitalization in this patient cohort. KEYWORDS: heart failure, drug therapy, drug provision, follow-up, AI. FOR CITATION: Dolgusheva Yu.A., Efremova Yu.E., Gornyakova N.B., Kudrina V.G., Ayrapetyan A.A., Mironov N.Yu., Bogdanova V.O., Sorokin E.V. Chronic heart failure: drug provision, follow-up and application potential of digital technologies. Russian Medical Inquiry. 2024;8(7):375–385 (in Russ.). DOI: 10.32364/2587-6821-2024-8-7-3.